February 13, 2024
A Texas federal judge said he could not entertain Big Pharma's challenge to the Biden administration's prescription drug pricing program since the only Texas-based trade group fighting the lawsuit failed to first bring its constitutional complaint to U.S. healthcare authorities.
October 06, 2023
Lawsuits from Big Pharma and big business challenging Medicare's new power to negotiate drug prices are hurtling toward pivotal tests of lofty legal theories and the Biden administration's creative efforts to save its signature health care accomplishment. Here, Law360 explores the litigation landscape in a detailed map that will be updated as the saga evolves.
September 01, 2023
Novartis Pharmaceuticals Corp. on Friday joined the growing list of pharmaceutical companies challenging the Inflation Reduction Act, filing suit in New Jersey federal court just days after the Biden administration revealed the list of drugs in the inaugural round of Medicare price negotiations.
August 14, 2023
A barrage of legal challenges to landmark legislation empowering Medicare to negotiate drug prices is little more than a failed lobbying campaign "masquerading as constitutional theory," the U.S. Department of Health and Human Services said in its first official rebuttal in the high-stakes litigation.
July 21, 2023
A head-spinning spree of rulings and new lawsuits in 2023's first half is reverberating across the health care industry and auguring a dizzying denouement in the year's final months that may well upend assumptions about drug prices and approvals, the False Claims Act and the powers of federal regulators.
July 11, 2023
Merck & Co. on Tuesday likened the Inflation Reduction Act's new system of drug-price negotiations to an oppressive political regime and derided the Biden administration's rush for legal cover amid a cloudburst of litigation as "highly dubious" and "constitutionally irrelevant."
June 21, 2023
A group that represents major pharmaceutical companies has lobbed yet another challenge to landmark legislation allowing Medicare to negotiate drug prices, saying in the lawsuit filed in Texas federal court Wednesday that the law harms innovation.